Sodium-Glucose Co-transporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have proven benefits on clinical outcomes in patients with heart failure (HF).1-6 However, this class of medications increases the risk of mycotic genital infections (MGIs) and urinary tract infections (UTIs), particularly within the first 3-6 months after their initiation.7,8,9 In the EMPEROR-Preserved and EMPEROR-Reduced trials, MGIs and UTIs were among the 3 most common adverse events in the empagliflozin group,1,2 highlighting the clinical relevance of these infections.

Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Angela Duvalyan, Ricardo M. La Hoz, Darren K McGuire, Mark H. Drazner Tags: Review Article Source Type: research